This study is testing two different doses of a new drug called ivonescimab, combined with standard chemotherapy (carboplatin and etoposide), for people with extensive-stage small cell lung cancer (ES-SCLC). Ivonescimab is a bispecific antibody, meaning it's a special protein designed to help your immune system fight cancer cells by targeting two different molecules at once. The study aims to find the best dose of ivonescimab that is both effective and safe. You could be eligible if you have ES-SCLC that hasn't been treated with other systemic therapies, are at least 18 years old, and have measurable disease. The study will measure how many people respond to the treatment and the rate of serious side effects over 18 months. The current recruitment status is unclear.

Study design

This is a randomized, open-label Phase II study involving 60 participants. Participants will be randomly assigned to receive one of two doses of ivonescimab.

What's involved

You will receive ivonescimab, carboplatin, and etoposide for four cycles (each 21 days long), followed by maintenance ivonescimab every 21 days until your disease progresses or you withdraw. Tumor tissue will be requested at the beginning of the study.

Compensation

Not stated in the trial record.

Follow-up

The main study outcomes, including response rate and serious side effects, will be measured at 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.